tiprankstipranks
Advertisement
Advertisement

TAK Stock Latest News

Takeda’s TAK-226 Anemia Trial Offers New Optionality in Hematology
Company AnnouncementsTakeda’s TAK-226 Anemia Trial Offers New Optionality in Hematology
4d ago
TAK
Takeda Extends TAK-360 Sleep Trial, Signaling Long-Term Ambitions in Narcolepsy
PremiumCompany Announcements
Takeda Extends TAK-360 Sleep Trial, Signaling Long-Term Ambitions in Narcolepsy
5d ago
TAK
Takeda’s Takhzyro Real‑World Pediatric Study Wraps Up, Setting the Stage for Next Moves
PremiumCompany Announcements
Takeda’s Takhzyro Real‑World Pediatric Study Wraps Up, Setting the Stage for Next Moves
6d ago
TAK
Takeda, the Indoensian Government announce collaboration
PremiumThe Fly
Takeda, the Indoensian Government announce collaboration
8d ago
TAK
Takeda Files July 2026 Corporate Governance Report Highlighting Full Code Compliance
PremiumCompany Announcements
Takeda Files July 2026 Corporate Governance Report Highlighting Full Code Compliance
11d ago
6K
TAK
Takeda Updates Articles of Incorporation in June 2026 SEC Filing
PremiumCompany AnnouncementsTakeda Updates Articles of Incorporation in June 2026 SEC Filing
21d ago
6K
TAK
Takeda Shareholders Approve Dividend and Board Slate at 150th Annual Meeting
Premium
Company Announcements
Takeda Shareholders Approve Dividend and Board Slate at 150th Annual Meeting
24d ago
6K
TAK
Takeda CEO Christophe Weber retires, Julie Kim succeeds
Premium
The Fly
Takeda CEO Christophe Weber retires, Julie Kim succeeds
27d ago
TAK
Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib
PremiumThe Fly
Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib
27d ago
TAK
Takeda’s New Polish Study Tracks Real-World Impact of Fruquintinib in Advanced Colorectal Cancer
PremiumCompany Announcements
Takeda’s New Polish Study Tracks Real-World Impact of Fruquintinib in Advanced Colorectal Cancer
1M ago
TAK
Takeda’s High-Stakes Overhaul: CEO Transition and Major Restructuring Raise Execution and Profitability Risks
PremiumCompany Announcements
Takeda’s High-Stakes Overhaul: CEO Transition and Major Restructuring Raise Execution and Profitability Risks
1M ago
TAK
Takeda presents additional results from oveporexton studies at SLEEP 2026
PremiumThe Fly
Takeda presents additional results from oveporexton studies at SLEEP 2026
1M ago
TAK
Takeda announces results for Phase 3 study of TAK-279
PremiumThe FlyTakeda announces results for Phase 3 study of TAK-279
1M ago
TAK
FDA accepts Takeda’s application for intravenous Entyvio
Premium
The Fly
FDA accepts Takeda’s application for intravenous Entyvio
1M ago
TAK
Takeda’s TAK-360 Narcolepsy Trial Moves Forward, Expanding Its Specialty CNS Pipeline
Premium
Company Announcements
Takeda’s TAK-360 Narcolepsy Trial Moves Forward, Expanding Its Specialty CNS Pipeline
1M ago
TAK
Takeda’s New Mezagitamab Trial Targets High-Risk Kidney Rejection, Bolstering Long-Term Pipeline Story
PremiumCompany Announcements
Takeda’s New Mezagitamab Trial Targets High-Risk Kidney Rejection, Bolstering Long-Term Pipeline Story
2M ago
TAK
Takeda’s Real-World Maribavir Study in Argentina: What Investors Should Watch
PremiumCompany Announcements
Takeda’s Real-World Maribavir Study in Argentina: What Investors Should Watch
2M ago
TAK
Innovent Biologics announces results from PoC study of IBI363
PremiumThe Fly
Innovent Biologics announces results from PoC study of IBI363
2M ago
TAK
Takeda to Revise FY2025 IFRS Earnings Report After U.S. AMITIZA Antitrust Verdict
PremiumCompany Announcements
Takeda to Revise FY2025 IFRS Earnings Report After U.S. AMITIZA Antitrust Verdict
2M ago
6K
TAK
Takeda Links Executive Pay to R&D Progress and TSR as FY2025 Results Reset Growth Path
PremiumCompany AnnouncementsTakeda Links Executive Pay to R&D Progress and TSR as FY2025 Results Reset Growth Path
2M ago
6K
TAK
Takeda CEO-Elect Julie Kim Sets Two-Horizon Growth Plan on Back of Strong FY2025 Pipeline and Results
Premium
Company Announcements
Takeda CEO-Elect Julie Kim Sets Two-Horizon Growth Plan on Back of Strong FY2025 Pipeline and Results
2M ago
6K
TAK
Takeda Details IFRS-Based Financial Notes and Group Restructuring in May 2026 Filing
Premium
Company Announcements
Takeda Details IFRS-Based Financial Notes and Group Restructuring in May 2026 Filing
2M ago
6K
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >